Ignite Creation Date:
2025-12-24 @ 4:07 PM
Ignite Modification Date:
2026-01-27 @ 7:22 AM
Study NCT ID:
NCT05800366
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-14
First Post:
2023-03-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Sponsor:
Jennifer Crombie, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-06
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-09-15
Completion Date Type:
ESTIMATED
First Submit Date:
2023-03-22
First Submit QC Date:
None
Study First Post Date:
2023-04-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-12
Last Update Post Date:
2025-03-14
Last Update Post Date Type:
ACTUAL